[go: up one dir, main page]

WO2004110349A3 - Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes - Google Patents

Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes Download PDF

Info

Publication number
WO2004110349A3
WO2004110349A3 PCT/US2004/015026 US2004015026W WO2004110349A3 WO 2004110349 A3 WO2004110349 A3 WO 2004110349A3 US 2004015026 W US2004015026 W US 2004015026W WO 2004110349 A3 WO2004110349 A3 WO 2004110349A3
Authority
WO
WIPO (PCT)
Prior art keywords
sars
epitopes
methods
cell epitopes
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/015026
Other languages
English (en)
Other versions
WO2004110349A2 (fr
Inventor
Morten Nielsen
Ole Lund
Claus Lundegaard
Peder Worning
Soren Buus
Soren Brunak
Sune Justesen
Christina Sylvester-Hvid
Gustav A Roder
Kasper Lamberth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Priority to CA002525778A priority Critical patent/CA2525778A1/fr
Publication of WO2004110349A2 publication Critical patent/WO2004110349A2/fr
Priority to IL171924A priority patent/IL171924A0/en
Anticipated expiration legal-status Critical
Publication of WO2004110349A3 publication Critical patent/WO2004110349A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Selon un premier aspect, l'invention concerne des épitopes de lymphocytes T situés dans le génome du virus du syndrome respiratoire aigu sévère (SRAS). Plus particulièrement, il existe 180 épitopes de peptides linéaires de classe I et 200 épitopes linéaires de classe II provenant du génome du virus du SRAS. Selon un deuxième aspect, l'invention concerne des variants de ces séquences. Selon un troisième aspect, l'invention concerne un procédé de prédiction de ces séquences à partir de données du génome et de validation des prédictions de manière expérimentale. Selon un quatrième aspect, l'invention concerne des compositions comprenant ces épitopes, destinées à être utilisées dans un vaccin et à induire une réaction des lymphocytes T chez un sujet, ou en tant qu'outil diagnostique.
PCT/US2004/015026 2003-05-14 2004-05-14 Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes Ceased WO2004110349A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002525778A CA2525778A1 (fr) 2003-05-14 2004-05-14 Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes
IL171924A IL171924A0 (en) 2003-05-14 2005-11-13 T cell epitopes useful in a severe acute respiratory syndrome (sars) virus vaccine and as diagnostic tools and methods for identifying same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300725 2003-05-14
DKPA200300725 2003-05-14

Publications (2)

Publication Number Publication Date
WO2004110349A2 WO2004110349A2 (fr) 2004-12-23
WO2004110349A3 true WO2004110349A3 (fr) 2006-03-23

Family

ID=33547529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015026 Ceased WO2004110349A2 (fr) 2003-05-14 2004-05-14 Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes

Country Status (3)

Country Link
CA (1) CA2525778A1 (fr)
IL (1) IL171924A0 (fr)
WO (1) WO2004110349A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2215108A4 (fr) * 2007-10-23 2012-07-04 Univ Colorado Inhibiteurs compétitifs de l'expression de chaînes invariantes et/ou d'une liaison d'un clip ectopique
EP2360173B1 (fr) * 2008-11-28 2016-01-13 NOF Corporation Peptide d'épitope de lymphocyte t cytotoxique pour le coronavirus sars, et utilisation de celui-ci
WO2018102317A1 (fr) * 2016-11-29 2018-06-07 The Regents Of The University Of California Modulation de p53 pour le traitement du cancer
EP3892297A1 (fr) * 2020-04-09 2021-10-13 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides et combinaisons de peptides à utiliser en immunothérapie contre une infection par le sars-cov-2 (covid-19)
CN111440229B (zh) * 2020-04-13 2021-08-03 中国人民解放军军事科学院军事医学研究院 新型冠状病毒t细胞表位及其应用
EP4138907A4 (fr) * 2020-04-20 2024-08-21 The General Hospital Corporation Composition immunogène de coronavirus à épitopes ayant un score de réseau élevé
CA3176320A1 (fr) * 2020-04-20 2021-10-28 Richard STRATFORD Vaccins contre le sars-cov-2
WO2021228853A1 (fr) * 2020-05-11 2021-11-18 Ose Immunotherapeutics Vaccin contre le virus sras-cov
WO2021256795A1 (fr) * 2020-06-15 2021-12-23 한국과학기술원 Épitope du nouveau coronavirus et son utilisation
AU2021293931A1 (en) * 2020-06-17 2023-01-19 Ahs Hospital Corp. SARS-CoV-2 immunodominant peptides and uses thereof
WO2022026921A1 (fr) * 2020-07-30 2022-02-03 Repertoire Immune Medicines, Inc. Identification et utilisation d'épitopes de lymphocytes t dans la conception d'approches diagnostiques et thérapeutiques associées à la covid-19
WO2022067062A1 (fr) * 2020-09-24 2022-03-31 Epivax, Inc. Développement rapide d'un vaccin prophylactique à large spectre pour le sars-cov-2 à l'aide d'un système d'administration d'antigène à médiation par phage
JP2023550094A (ja) * 2020-11-12 2023-11-30 ティースキャン セラピューティクス インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用
CN112876542B (zh) * 2021-02-08 2021-10-29 暨南大学 一种新型冠状病毒t细胞的抗原表位肽及其应用
WO2022178216A2 (fr) * 2021-02-22 2022-08-25 Cotropia Joseph Antigènes et épitopes de virus corona et protéines se liant à ceux-ci
US20240181070A1 (en) * 2021-04-08 2024-06-06 Ramot At Tel-Aviv University Ltd. Nanovaccines for treatment of viral diseases
WO2022268916A2 (fr) 2021-06-23 2022-12-29 Ose Immunotherapeutics Vaccin peptidique pan-coronavirus
CN113666989B (zh) * 2021-08-12 2023-08-29 中国科学技术大学 新型冠状病毒cd8+ t细胞表位肽及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] "putative orflab polyprotein (SARS coronavirus)", accession no. NCBI Database accession no. (NP828849) *
XU Z ET AL: "The R Protein of SARS-CoV: Analyses of Structure and Function Based on Four Copmlete Genome Sequences of Isolates BJ101-BJ104.", GENOMICS PROTEOMICS BIOINFORMATICS, vol. 1, no. 2, May 2003 (2003-05-01), pages 155 - 165, XP001182393 *

Also Published As

Publication number Publication date
CA2525778A1 (fr) 2004-12-23
IL171924A0 (en) 2006-04-10
WO2004110349A2 (fr) 2004-12-23

Similar Documents

Publication Publication Date Title
WO2004110349A3 (fr) Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes
WO2004074455A3 (fr) Variants de la region fc
DE602004024542D1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
WO2005042767A3 (fr) Compositions et procedes de detection du coronavirus du syndrome respiratoire aigu
WO2005111212A3 (fr) Code-barres biologique
IL164966A0 (en) 3?-Ä2Z)-Ä1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylideneÜhydrazinoÜ-2'-hydroxy-Ä1,1'-biphenylÜ-3-carboxylic acid bis-(monoethanolamine)
DE50208862D1 (de) Gasturbogruppe
NZ543467A (en) The severe acute respiratory syndrome coronavirus
UA84284C2 (ru) Способы лечения, профилактики и диагностики инфекции helicobacter cerdo
WO2007092645A3 (fr) Nouvelles combinaisons d'inhibiteurs du vhc et méthodes
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
DK1399590T3 (da) Happier kortlægning
DE50209684D1 (de) Gasturbogruppe
WO2009030770A3 (fr) Procédés et outils de diagnostic de cancer chez des patients er-
NO20044398L (no) Fotokatalysatorer inneholdende titanoksyd, samt fremgangsmate og anvendelse derav
WO2005051313A3 (fr) Procedes et reactifs pour le traitement, la prevention et le diagnostic d'infection par le bunyavirus
SG169325A1 (en) Promoters for expression in modified vaccinia virus ankara
WO2005035794A3 (fr) Detection du sdrp
WO2004091524A3 (fr) Vaccins contre des virus des voies respiratoires
ATE542810T1 (de) Verfahren zur herstellung von 3,5-di-omikron-acyl-2-fluor-2-c-methyl-d-ribono gamma-lacton
WO2004029835A3 (fr) Systeme et procede d'association de differents types de contenus multimedia
WO2005037855A3 (fr) Epitopes de lymphocytes t convenant pour un vaccin contre la peste et comme outils de diagnostic, et procede d'identification correspondant
WO2007120120A3 (fr) Virus parainfluenza humain atténué, procédés et utilisations associés
DE60224280D1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
NO20052680D0 (no) Forbedringsmiddel inneholdende brennstoff.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 171924

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2525778

Country of ref document: CA

122 Ep: pct application non-entry in european phase